A public-private consortium designs a new therapy to treat solid tumours
Expansión, El Periódico de Catalunya and Diario de Córdoba, among other media, have published articles about the biotechnologist Iproteos, a company created in 2011 by the scientists Teresa Tarragó and Ernest Giralt and based on the transfer of a technology developed atIRB Barcelona and the University of Barcelona (UB).
The origin of cancer: a magnifying glass to investigate the Big Bang tumor
SINC AGENCY & OTHER MEDIA
SINC, El Público, Catalunya Vanguardista and the newspaper Heraldo de Aragón, have published an article about the process and conditions that triggers cancer according to a study published in the journal Science that raises new theories about aging.
A study suggests that epigenetic therapies could lead to the appearance of aggressive tumors
LA VANGUARDIA & OTHER MEDIA
La Vanguardia, Cope, Revista Genética, among other media, have each published an article about the latest study led by ICREA researchers Salvador Aznar Benitah and Fran Supek.
Lara Barrio
Postdoctoral Fellow
“From our study in Drosophila flies we can deduce that it would be particularly interesting to address vertebrates and analyse the participation of p53 in diabetes and obesity”
More on this news here
Felice Alessio Bava
IRB Barcelona Alumni member
«We suspected that CPEB1, a protein involved in regulating mRNA translation in the cytoplasm, might also be active in the nucleus and play a role in controlling pre-mRNA processing. We discovered that it affects the alternative generation in the mature mRNA of the 3'-UTR, regions where most of the elements regulating translation in time and space are located.»
More info about this news here.
Jalaj Gupta
Postdoctoral Fellow
«Our study highlights the complexity of p38 functions, both in cancer and in the maintenance of normal tissues. It shows why an inhibitor of this molecule could effectively have undesirable side effects. But these do not exclude it from being a target against cancer.»
More on this news here.
Meritxell Teixidó
Research Associate
«98% of the potential therapeutic molecules against diseases of the central nervous system cannot cross the blood-brain barrier. We develop peptides with the capacity to open the doors of the barrier and act as shuttles when attached to a therapeutic molecule.»
Laura Nevola
Alumni - Research Associate
«Controlling a biological process from outside is the future of chemistry and opens up promising roads for advancements in pharmacological research.»
More info on this news here.
Laura Boulan
PhD Student
«I discovered that the bantam molecule drives the transition from larva to pupa, the phase analogous to human adolescence.»
More info about this news here.
Eduard Batlle
Group Leader
Group: Colorectal cancer laboratory
«We need to look at the soil, not at the seed. TGF-beta is the fertiliser that changes the earth in which the tumour seed grows.»
More info about this news here.
IRB Barcelona has been awarded the "HR Excellence in Research" logo. This recognition reflects the commitment of the Institute to continuously improving its human resources policies in line with the European Charter for Researchers and the Code of Conduct for the Recruitment of Researchers. The award confirms the efforts of the Institute to ensure fair and transparent recruitment and appraisal procedures. Click here for more information.
IRB Barcelona is home to nearly 450 research, technical and support staff from 35 countries who share the common goal of contributing to the advancement of the biomedical sciences through investigator–driven research, and improving quality of life by applying advances in this field.
The convergence of biology, chemistry, and structural and computational biology is unique at IRB Barcelona and opens a strategic window to gain insight into basic molecular processes in health and disease.
Research is conducted by 23 groups organized into 5 interdisciplinary programmes. Each programme includes a diverse faculty of researchers with overlapping scientific interests. The research areas have been structured to be highly interactive, fostering multidisciplinarity by combining modern molecular biology, classical genetics, biochemistry, structural biology, bioinformatics, systems biology, advanced microscopy, and genomic and proteomic approaches.
Our Board of Trustees comprises members of the Catalan Government (from the Department of Economy and Competitivity and the Department of Health), the University of Barcelona, a representative from the BBVA Foundation as well as internationally renowned scientists.
